Company Overview and News


Add ALXN
to your dashboard

Headline News

The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex

2018-01-12 zacks
Chicago, IL – January 12, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Celgene, Inc. (CELG - Free Report) , Amgen, Inc. (AMGN - Free Report) , Exelixis, Inc. (EXEL - Free Report) , Alexion Pharmaceuticals, Inc. (344-0)

Short Sellers Grow More Selective on Major Biotechs

2018-01-11 247wallst
The short interest data are out for the most recent settlement date, December 29. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with big potential upside and big potential downside. The health care sector in general has rallied since Donald Trump won the presidency, but now that the fate of the ACA is uncertain, the health care rally is called into question. (287-0)

Can Biotech Keep Last Year's Momentum Alive in 2018?

2018-01-11 zacks
The year 2017 has been better than expected for the biotech sector. The NASDAQ Biotechnology index was up 18.7% in 2017. While drug pricing issue, competition and a slowdown in growth of key drugs are expected to remain a hangover in 2018 as well, approval of new drugs and strategic acquisitions by several big wigs in 2017 are likely to boost investors’ sentiments. Thus 2018 needless to say, holds promise for generating stellar returns. (224-0)

A Look at Ionis Pharmaceuticals’ January 2018 Valuation

2018-01-10 editors.aws.marketrealist
Ionis Pharmaceuticals (IONS), a leading RNA-targeted (ribonucleic acid) therapeutic development company, is focused on developing new best-in-class drugs for life-threatening diseases and marketing its approved products in collaboration with other pharmaceutical companies. (57-0)

Achillion Pharmaceuticals: Ultra-Rare Disease Company With Ultra-Rare Enterprise Value

2018-01-09 seekingalpha
Achillion (ACHN) is a biopharmaceutical company specializing in discovering and developing small molecules for complement-mediated diseases. (303-2)

10 Strong Buy Stocks From 2017’s Best Analysts

2018-01-08 investorplace
What are the top analysts who consistently get it right recommending strong buy stocks for 2018? TipRanks tracks and measures the performance of over 4,700 analysts to identify the top experts in each sector who consistently outperform the market. (388-4)

Valuation Dashboard In Healthcare - New Year's Update

2018-01-08 seekingalpha
Biotechnology is the only Healthcare industry looking underpriced relative to its historical valuation averages, but profitability measured in ROE is below its historical baseline. Healthcare Providers are moderately overpriced (about 20%) and close to their historical baseline in profitability. Healthcare Equipment is the most overpriced group. Life Science Tools/Services has a profitability factor above its historical average, which may partly justify overpricing. (40-0)

Alexion Pharmaceuticals: A High Conviction, Large Cap Orphan Disease Pick For 2018

2018-01-08 seekingalpha
We are initiating coverage on Alexion Pharmaceuticals stock with a Buy rating and first price target of $170, 1-2 year time frame. (77-0)

Atara Biotherapeutics: Buy The Secondary

2018-01-08 seekingalpha
Shares have risen just 10% in the past year and haven't achieved much since their IPO. (244-0)

Stocks To Watch: CES Headlines Blockbuster Conference Slate

2018-01-06 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (861-8)

Omeros Inks Agreement With FDA for OMS721 Phase III Trial

2018-01-04 zacks
Omeros Corporation (OMER - Free Report) announced that it has entered into an agreement with the FDA on its protocol to start a phase III study to evaluate its lead pipeline candidate, OMS721, for treatment of patients with IgA nephropathy (IgAN). Enrollment of patients for the study is expected to start early next month. (504-1)

Spark Should Spark a Pricing Trend - Bloomberg Gadfly

2018-01-04 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (130-0)

Will These 2 Large-Cap Biotechs Be on Investor Radar in '18?

2018-01-03 zacks
In this blog, we highlight two large-cap biotech stocks — Vertex Pharmaceuticals, Inc. (VRTX - Free Report) and Alexion Pharmaceuticals, Inc. (ALXN - Free Report) — that attracted investor attention last year and will likely remain in focus in the New Year as well. (40-0)

PRESS DIGEST -Wall Street Journal - Jan 3

2018-01-03 reuters
Jan 3 (Reuters) - The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy. (80-0)

Alexion Agrees to Work With Hedge Fund Elliott on Filling Board Seat - WSJ

2018-01-03 wsj
Alexion Pharmaceuticals Inc. said Tuesday it will work with hedge fund Elliott Management Corp. on filling an open board seat. (115-1)

CUSIP: 015351109